A purple and pink letter v on a white background.
April 2, 2019

Preventing PIH: The Top Causes, Risks, and Treatments

When it comes to skin concerns, uneven texture is top of mind for many aesthetics patients. Among the top skin tone and texture issues treated, rosacea, bumps, acne scars, and stretch marks are some of the most common, alongside uneven pigmentation. In fact, one survey from the American Society for Dermatologic Surgery(ASDS) reports that 71% of aesthetic patients are concerned with skin tone and texture. Unfortunately, conditions like these can be tough to treat.

Skin resurfacing treatments are currently the best tools available to medical aesthetics practitioners for treating these common tone and texture issues; however, not all treatments are created equally. Results can vary quite a bit between devices, protocols, and other factors, such as a patient not wearing sunscreen. However, one factor that remains the same across skin resurfacing treatments and patients is a concern for post-inflammatory hyperpigmentation (PIH).

What Is PIH?

Post-inflammatory hyperpigmentation (PIH) results from an overproduction or uneven disbursement of melanin in the skin as a natural reaction to injury and defense against inflammation. PIH presents as flat, discolored spots on the skin, resulting in an uneven skin tone. While there is no medical concern associated with PIH, it certainly contributes to the demand for skin resurfacing solutions to treat patients’ skin tone and texture concerns.

Top Causes of PIH

For many, inflammation that may prompt PIH is most often due to acne vulgaris (pimples), atopic dermatitis (eczema/rash), and impetigo (bacterial infection). UV exposure, insect bites, allergic reactions, chronic diseases like psoriasis, or side effects from certain medications may also increase one’s risk of PIH, as well as some medical aesthetic procedures if not done correctly.

Patients Most at Risk of PIH

PIH can certainly occur in all skin types and tones, but those with darker skin tones are most at risk. More specifically, the Journal of Clinical and Aesthetic Dermatology reports that those with Fitzpatrick skin types IV to VI—which actually comprises a significant portion of the global aesthetic market, as this includes most Latin Americans, Asians, Pacific Islanders, people of African descent, people of Middle Eastern descent, and the Indigenous peoples of North America—are at highest risk of experiencing PIH. Unfortunately, there are few skin resurfacing treatments that are safe for patients with these skin types, meaning your clinic could lose out on a large number of prospective patients—but only if you’re unprepared.

How to Treat and Prevent PIH

Since PIH causes an uneven skin tone, it’s one of the many reasons people seek skin resurfacing treatments. It’s important to note, though, that some treatments cause additional inflammation and worsening of the condition—especially in darker skin tones. There are safer skin resurfacing treatments for these patients, though.  

For clinics committed to offering advanced aesthetic treatments to a more diverse patient base and building out a strong patient referral program, choosing the right device can make a world of difference. Get started on the right track with our comprehensive report, PIH and Cosmetic Procedures: Safe Skin Resurfacing Options for Patients Concerned about PIH , that covers the risks associated with PIH and skin resurfacing treatments, as well as the top advances in medical aesthetic technology that can help you deliver outstanding results to your prospective patients. Simply click the Download Now button below to access the report today!

July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.
May 22, 2026
Skin cancer radiotherapy improves treatment precision and patient outcomes. Learn how dermatology clinics use it in modern care plans.